SAN FRANCISCO, Jan. 4 /PRNewswire/ -- Intarcia Therapeutics, Inc., a privately held, biopharmaceutical company, today announced that it will present at the 24th Annual JPMorgan Healthcare Conference at 1:00 p.m. PST on Thursday, January 12, 2006, at the Westin St. Francis Hotel in San Francisco, California.
(Logo: http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO )
Alice Leung, President and Chief Executive Officer of Intarcia Therapeutics, will provide an update on the Company’s clinical development program for the Atamestane combination therapy in hormone-dependent advanced breast cancer. Intarcia expects to announce results from its first phase 3 clinical trial of Atamestane in April 2006. The Company will also provide an update on its development program for Omega DUROS(R), a subcutaneous implant designed to deliver omega interferon for the treatment of hepatitis C.
About Intarcia
Intarcia Therapeutics, Inc., a privately held biopharmaceutical company, applies a targeted approach to the acquisition, development and commercialization of therapeutic products for use in treating patients with cancer and infectious diseases. Intarcia’s lead programs include a combination therapy for the treatment of hormone-dependent breast cancer in postmenopausal women and an implant to deliver omega interferon for the treatment of hepatitis C.
Photo: http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comIntarcia Therapeutics, Inc.
CONTACT: James Ahlers, Chief Financial Officer of Intarcia Therapeutics,Inc., +1-510-652-2600, ext. 235
Web site: http://www.intarcia.com/
